With CLDN-5 and VE-cad as the potential target proteins of FGFC1, this study provides the regulatory factors for FGFC1 reducing the risk of bleeding transformation following its application in thrombolytic therapy for cerebral thrombosis. The gene discussed is CLDN5; the disease is intracranial thrombosis.